ARV Facts

Facts about Antiretroviral Drugs

Arrow to the left Back to the Homepage

Active substance: Tipranavir
Manufacturer: Boehringer-Ingelheim (Germany / USA)
 

Extract from the patient information:

"Patients should be informed that APTIVUS is not a cure for HIV-1 infection and that they may continue to develop opportunistic infections and other complications associated with HIV disease. The long-term effects of APTIVUS are unknown at this time."

Known side effects: more immune deficiency

“Adverse Reactions Reported in Randomized, Controlled Clinical Trials (1182.12 and 1182.48) Based on Treatment-Emergent Clinical Adverse Reactions of Moderate to Severe Intensity (Grades 2 - 4) in at least 2% of Treatment-Experienced Subjects in either Treatment Groupa (48 week Analyses):
Neutropenia: 2.0% (2.0)”

“Blood and Lymphatic System Disorders: thrombocytopenia

Neutropenia = Decrease of neutrophils, a subtype of white blood cells
Thrombocytopenia = Low levels of platelets (blood cells required for coagulation) due to toxic effects of ARVs on blood cell formation in the bone marrow

The above has been extracted from the Aptivus patient information on the Boehringer-Ingelheim webpages.